Arab Press

بالشعب و للشعب
Saturday, May 31, 2025

From COVID to Cancer: Pfizer's Shopping Spree Continues with $43 Billion Seagen Acquisition

Pfizer is looking beyond the COVID-19 pandemic and making some major moves in the world of cancer treatments. The pharmaceutical giant has just announced a $43 billion deal to acquire Seagen, a leading innovator in targeted cancer therapies.
This latest acquisition by Pfizer will add four approved cancer therapies to their portfolio, which together generated nearly $2 billion in sales in 2022. Seagen is a pioneer in antibody-drug conjugates, which essentially work like "guided missiles" designed to target and destroy cancer cells while leaving healthy cells unharmed.

CEO Albert Bourla says that this deal will help Pfizer move into an area that is more protected from regulatory and patent issues. It's also a smart move for Seagen, as the Biden administration's Inflation Reduction Act is set to benefit the company's expensive treatments, which will be more accessible to patients with out-of-pocket healthcare spending caps.

Pfizer will pay $229 in cash per Seagen share, a 32.7% premium to Friday's closing price, which sent Seagen's shares soaring to $200 in early trading.

This acquisition comes as Pfizer is preparing for a significant decline in COVID-19 product sales and stiff competition for some of its top-selling drugs. The company expects to generate more than $10 billion in sales from Seagen products alone by 2030, in addition to the $15 billion from its other recent acquisitions.

Pfizer's recent deals include the purchase of Global Blood Therapeutics for $5.4 billion, migraine drug maker Biohaven Pharmaceutical Holding for $11.6 billion, and drug developer Arena Pharmaceuticals for $6.7 billion.

Pfizer's current portfolio of oncology therapies includes 24 approved drugs, while Seagen's includes Adcetris for lymphoma, Padcev for bladder cancers, Tivdak for cervical cancer, and breast cancer treatment Tukysa.

The deal is expected to be completed in late 2023 or early 2024, and while antitrust regulators may closely review it due to its size, Pfizer believes it will eventually be approved.

This is definitely one to watch as Pfizer makes bold moves in the world of cancer treatments and continues to diversify its portfolio beyond COVID-19 products.
Comments

Oh ya 2 year ago
Maybe they are doing this because of the spike in cancer in people who have taken the clot shot. Making money at both ends.

Newsletter

Related Articles

Arab Press
0:00
0:00
Close
Meta and Anduril Collaborate on AI-Driven Military Augmented Reality Systems
EU Central Bank Pushes to Replace US Dollar with Euro as World’s Main Currency
European and Arab Ministers Convene in Madrid to Address Gaza Conflict
Head of Gaza Aid Group Resigns Amid Humanitarian Concerns
U.S. Health Secretary Ends Select COVID-19 Vaccine Recommendations
Trump Warns Putin Is 'Playing with Fire' Amid Escalating Ukraine Conflict
India and Pakistan Engage Trump-Linked Lobbyists to Influence U.S. Policy
U.S. Halts New Student Visa Interviews Amid Enhanced Security Measures
Trump Administration Cancels $100 Million in Federal Contracts with Harvard
SpaceX Starship Test Flight Ends in Failure, Mars Mission Timeline Uncertain
King Charles Affirms Canadian Sovereignty Amid U.S. Statehood Pressure
Iranian Revolutionary Guard Founder Warns Against Trusting Regime in Nuclear Talks
Netanyahu Accuses Starmer of Siding with Hamas
Calls Grow to Resume Syrian Asylum Claims in UK
UAE Offers Free ChatGPT Plus Subscriptions to Citizens
Denmark Increases Retirement Age to 70, Setting a European Precedent
Iranian Director Jafar Panahi Wins Palme d'Or at Cannes
Israeli Airstrike Kills Nine Children of Gaza Doctor
Lebanon Initiates Plan to Disarm Palestinian Factions
Iran and U.S. Make Limited Progress in Nuclear Talks
Trump Administration's Tariff Policies and Dollar Strategy Spark Global Economic Debate
OpenAI Acquires Jony Ive’s Startup for $6.5 Billion to Build a Revolutionary “Third Core Device”
Turkey Weighs Citizens in Public as Erdoğan Launches National Slimming Campaign
UK Suspends Trade Talks with Israel Amid Gaza Offensive
Iran and U.S. Set for Fifth Round of Nuclear Talks Amid Rising Tensions
Russia Expands Military Presence Near Finland Amid Rising Tensions
Indian Scholar Arrested in Crackdown Over Pakistan Conflict Commentary
Israel Eases Gaza Blockade Amid Internal Dispute Over Military Strategy
President Biden’s announcement of advanced prostate cancer sparked public sympathy—but behind closed doors, Democrats are in panic
Mount Lewotobi Laki-Laki Erupts Again, Spewing Ash Cloud over Flores Island
Indian jet shootdown: the all-robot legion behind China’s PL-15E missiles
The Chinese Dragon: The True Winner in the India-Pakistan Clash
Australia's Venomous Creatures Contribute to Life-Saving Antivenom Programme
The Spanish Were Right: Long Working Hours Harm Brain Function
Did Former FBI Director Call for Violence Against Trump? Instagram Post Sparks Uproar
US and UAE Partner to Develop Massive AI Data Center Complex
Apple's $95 Million Siri Settlement: Eligible Users Have Until July 2 to File Claims
US and UAE Reach Preliminary Agreement on Nvidia AI Chip Imports
President Trump and Elon Musk Welcomed by Emir of Qatar Sheikh Tamim with Cybertruck Convoy
Strong Warning Issued: Do Not Use General Chatbots for Medical, Legal, or Educational Guidance
NVIDIA and Saudi Arabia Launch Strategic Partnership to Establish AI Centers
Trump Meets Syrian President Ahmad al-Shara in Historic Encounter
US and Saudi Arabia Sign Landmark Agreements Across Multiple Sectors
Why Saudi Arabia Rolled Out a Purple Carpet for Donald Trump Instead of Red
Elon Musk Joins Trump Meeting in Saudi Arabia
Trump says it would be 'stupid' not to accept gift of Qatari plane
Quantum Computing Threatens Bitcoin Security
Michael Jordan to Serve as Analyst for NBA Games
Senate Democrats Move to Censure Trump Over Qatar Jet Gift
Hamas Releases Last Living US Hostage from Gaza Amid Ongoing Conflict
×